Clinical trials: Hereditary Retinal Dystrophy
Retinitis Pigmentosa
Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation
This trial employs a single-arm, open-label seamless Phase I/II design, consisting of two stages: Phase I dose exploration and Phase II dose expansion.The primary objective of this trial is to evaluate the safety, tolerability…
- Trial name
- ZVS203e (NCT06952842)
- Testing
- ZVS203e
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chigenovo Co., Ltd
Retinitis Pigmentosa, Retinal Diseases
Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa
The purpose of the study is to evaluate the safety and tolerability of a single intravitreal injection of virally-carried Multi-Characteristic Opsin I (vMCO-I)
- Conditions
- Retinitis Pigmentosa, Retinal Diseases, Retinal Degeneration
- Trial name
- NCT04919473
- Testing
- Gene Therapy product:vMCO-I
- Where
- India
- Volunteers
- 11 people
- Sponsor
- Nanoscope Therapeutics Inc.
Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy
This open-label, multi-center study is to evaluate the safety, tolerability, and efficacy of escalating doses of a gene therapy called SPVN20 administered via a single intravitreal injection in participants with advanced Rod-Cone…
- Trial name
- NYRVANA (NCT07807111)
- Testing
- SPVN20 (high dose), SPVN20 (medium dose), SPVN20 (low dose)
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 27 people
- Sponsor
- SparingVision
Choroidal Ischemia, Vitelliform Macular Dystrophy
Sildenafil for Treatment of Choroidal Ischemia
The hypothesis of this study is to determine if there is a benefit afforded by the use of systemic Sildenafil to patients with choroidal and retinal degenerations and dystrophies, such as vitelliform degeneration, dry and…
- Conditions
- Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy
- Trial name
- NCT04356716
- Testing
- Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Columbia University
Retinitis Pigmentosa
Study of Usher Syndromes, Type 1 and Type 2
The purpose of this investigation is to gain additional knowledge about what causes type 1 and type 2 Usher syndrome-inherited diseases that can cause balance problems and impaired hearing and vision-and to develop better…
- Trial name
- NCT00001347
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- National Eye Institute (NEI)
Pigmentary Retinopathy
Impact of Visual Field Restriction on Visual Exploration
To communicate with the observer and guide his gaze on the canvas, painters have developed different stylistic processes that artists, in the manner of scientists, have acquired on the functioning of human visual perception.
- Trial name
- REVE (NCT04360291)
- Testing
- Eye tracker
- Where
- France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Stargardt Disease, Retinitis Pigmentosa (RP)
Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration
The objective of this study is to evaluate the efficacy and safety of the PRIMA Products in participants with inherited retinal degeneration affecting the macula (including but not limited to Stargardt disease, and Retinitis…
- Conditions
- Stargardt Disease, Retinitis Pigmentosa (RP), Inherited Retinal Degeneration
- Trial name
- PRIMAlia (NCT07266584)
- Testing
- PRIMA Products
- Where
- Australia
- Volunteers
- 5 people
- Sponsor
- Science Corporation
Retinitis Pigmentosa
Observational Study of the Argus® II Retinal Prosthesis System
The Argus II Retinal Implant is a revolutionary new device, which offers vision to patients who are blind from retinal degeneration - retinitis pigmentosa. These patients have no alternatives.
- Trial name
- NCT01999049
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto